Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$61M+6.4% YoY

Gross Profit

$27M44.4% margin

Operating Income

-$24M-38.9% margin

Net Income

-$24M-39.6% margin

EPS (Diluted)

$-1.70

QoQ Revenue Growth

+17.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$772M

Total Liabilities

$413M

Stockholders' Equity

$359M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$61M	$57M	+6.4%
Gross Profit	$27M	$33M	-17.4%
Operating Income	-$24M	$331,000	-7267.1%
Net Income	-$24M	-$4M	-564.0%

Revenue Segments

Sales of generic pharmaceutical products

$42M68%

Sales of branded pharmaceutical products

$15M24%

Sales of contract manufactured products

$3M5%

Product development services

$978,0002%

Royalties from licensing agreements

$585,0001%

Other

$289,0000%

Geographic Segments

United States

$60M98%

Canada

$1M2%